Skip to main content
. 2023 Apr 4;55(4):1210–1221. doi: 10.4143/crt.2022.1633

Fig. 3.

Fig. 3

Evolution of human epidermal growth factor receptor 2 (HER2) status from primary breast cancer (BC) tumors to residual diseases after neoadjuvant chemotherapy (NACT) in all (A), hormone receptor (HR)–negative (B), and HR-positive (C) patients.